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ABSTRACT
CKD is increasingly prevalent in pregnancy. In the Torino-Cagliari Observational Study (TOCOS), we
assessed whether the risk for adverse pregnancy outcomes is associated with CKD by comparing pregnancy
outcomesof 504 pregnancies inwomenwithCKD tooutcomesof 836 low-risk pregnancies inwomenwithout
CKD. The presence of hypertension, proteinuria (.1 g/d), systemic disease, and CKD stage (at referral) were
assessed at baseline. The following outcomes were studied: cesarean section, preterm delivery, and early
preterm delivery; small for gestational age (SGA); need for neonatal intensive care unit (NICU); new onset of
hypertension; new onset/doubling of proteinuria; CKD stage shift; “general” combined outcome (preterm
delivery, NICU, SGA); and “severe” combined outcome (early preterm delivery, NICU, SGA). The risk for
adverse outcomes increased across stages (for stage 1 versus stages 4–5: “general” combined outcome,
34.1% versus 90.0%; “severe” combined outcome, 21.4% versus 80.0%; P,0.001). In women with stage 1
CKD, preterm delivery was associated with baseline hypertension (odds ratio [OR], 3.42; 95% confidence
interval [95% CI], 1.87 to 6.21), systemic disease (OR, 3.13; 95% CI, 1.51 to 6.50), and proteinuria (OR, 3.69;
95%CI, 1.63 to 8.36). However, stage 1CKD remainedassociatedwith adverse pregnancyoutcomes (general
combined outcome) inwomenwithout baseline hypertension, proteinuria, or systemic disease (OR, 1.88; 95%
CI, 1.27 to 2.79). The risk of intrauterine deathdid not differ betweenpatients and controls. Findings from this
prospective study suggest a “baseline risk” for adverse pregnancy-related outcomes linked to CKD.
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CKD is increasingly encountered in pregnancy.1,2
Several studies suggest that even in the early stages,
CKD is a relevant risk factor for adverse pregnancy
outcomes.3–5 These data partially contrast with one
population-based study that did not find an additive
risk for mild GFR reduction, thus suggesting that the
clinical definition of CKD is more complex than the
mere evaluation of GFR.6
Overall, quantifying the risks ofCKDinpregnancy
is also difficult because of the high heterogeneity of
kidney diseases, stages, and clinical presenta-
tions.4,7–11 A few points are clear: The risk of
adverse pregnancy-related outcomes is high in ad-
vanced CKD, and the disease may progress during
pregnancy.2,11,12 The increase in risk was clearly de-
scribed in previous articles in which kidney diseases
were “graded” in severity according to serum
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creatinine levels, thus strengthening the importance of renal
function reduction, however assessed.13–15
Specific diseases such as SLE or diabetic nephropathy may
bear higher risks, even if no comparative data analyzing various
kidney diseases in different stages are available to date.13–16
Other diseases such as IgA or reflux nephropathy usually
display a good prognosis, at least in the presence of normal
kidney function.17–23
Despite rising interest, few large cohorts of nonselected
patients with CKD encompassing the most frequently en-
countered disorders in clinical practice are available.
TheTorino-CagliariObservational Study (TOCOS)merges
the two largest Italian cohorts of CKD patients followed-up in
pregnancy between 2000 and 2013. We analyzed data con-
cerning 508 singleton deliveries (504 live births) from 731
referred pregnancies and compared them with a low-risk,
homogeneously followed-up population (839 singletons, 836
live births). Our aim was to identify the main determinants of
risk for adverse pregnancy-related outcomes in the CKD pop-
ulation,withparticularattention to the large stage1CKDsubsetof
patients, inwhompregnancy-related risks are already higher than
in the overall population, butwhose kidney function is still within
the normal range.
RESULTS
Baseline Data
Baseline data of the patients and of the controls are reported in
Table 1 and in Figures 1 and 2.
The twocohorts inTurin andCagliari reflect thedemographic
composition of the two Italian regions, Piedmont and Sardinia,
according to Ministry of Health data from the Italian National
Institute of Statistics (ISTAT) (Table 1).
No significant differences were observed between the two
control groups referring to the Turin Maternal-Fetal Unit.
Conversely, the significant difference in age at pregnancy in the
Cagliari cohort reflects a tendency to postpone pregnancy,
which is characteristic for the whole Sardinia region.24,25
No significant differences were observed with regard to
body mass index (BMI) and educational levels across patients
and controls. The BMI range was higher among the patients
because morbid obesity was considered a hallmark of “high-
risk” pregnancies and was not present in controls. The prev-
alence of non-Caucasian mothers was higher among patients
and controls that reside in the large multiethnic city of Turin
compared with Cagliari, in keeping with the low migration
flows of the Sardinian population.26
Table 2 summarizes the main baseline clinical data of the
two patient populations followed-up in Turin and Cagliari.
In both cohorts, patients in early CKD stages accounted for
the majority of the observed cases, in keeping with the
distribution of CKD in the childbearing age groups. The higher
prevalence of glomerular diseases in the Cagliari group and of
interstitial diseases in the Turin group are in keeping with
the main referral characteristics of the two nephrology units:
The Turin unit is linked with a large Urology ward, whereas the
Cagliari unit is a regional referral center for glomerular diseases.
The higher prevalence of diabetic nephropathy is consistent with
the high prevalence of type 1 diabetes in Sardinia. These
differences in the distribution of baseline diseases explain the
higher prevalence of hypertension (higher in glomerulardiseases
and diabetic nephropathy) and of stage 2 CKD in Cagliari.
Maternal-Fetal Outcomes in Patients and Controls
Table 3 reports the main outcomes of patients and controls,
considering the pregnancies that resulted in a live-born baby.
In the control groups, the prevalence of cesarean sections was
lower than the national average (38.8% in Italy in 200924–26).
Piedmont and Sardinia are regions of average-high and average-
low incidence with respect to Italy (37.1% in Sardinia and 29.9%
in Piedmont, according to ISTAT 2010 data).25,26 The incidence
of “late preterm” deliveries (34–37 weeks) is higher in Cagliari,
likely as a reflection of a more “aggressive” policy toward cesar-
ean sections, whereas the incidence of early preterm deliveries, a
harder outcome that is less affected by standard policies, is not
statistically different in the two settings (Table 3).
In all of the control cohorts, the incidence of hypertensive
disorders of pregnancy was lower than in the general Italian
population (overall 12%), thus supporting the definition of
“low-risk” cohorts (Table 3). Within this frame, the incidence
of hypertensive disorders of pregnancy was higher in the
Table 1. Main baseline data in the patients and in the controls (live births, singleton deliveries)
Characteristic
Controls Patients P Value for Patients
versus ControlsTurin Cagliari All P Value Turin Cagliari All P Value
Pregnancies (n) 559 277 836 336 168 504
Age at pregnancy (yr) 28.964.8 32.165.7 29.965.3 ,0.001 30.965.5 33.765.0 31.965.4 ,0.001 ,0.001
Parity (nulliparous) 61.2 52.0 58.1 0.01 58.6 51.2 56.2 0.14 0.48
BMI 22.663.3 21.963.3 22.463.3 0.01 23.164.8 23.665.1 23.364.9 0.35 0.001
Caucasian 80.1 97.8 86.0 ,0.001 87.5 99.4 91.5 ,0.001 0.004
Education level (.8th grade) 60.9 73.3 63.8 0.01 66.0 66.2 66.1 1.00 0.48
Data are presented as the mean6SD or percentage, unless otherwise indicated. The prevalence of Italian patients is 73.99% for Turin and 94.56% for Cagliari.
According to ISTAT data, median age at delivery is 32.6 years for Italian mothers and 29.3 years for foreign mothers. In Italy, Caucasian mothers make up 92.7% of
the cohort; 66.7% of the mothers have an educational level .8th grade. Age at pregnancy is 1 year higher in Sardinia versus the rest of Italy (ISTAT 2008).
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Cagliari controls compared with the Turin controls, in keeping
with the older age at pregnancy and a greater predisposition to
juvenile hypertension in this region (Sardinia)27 (Tables 1 and 3).
As expected, most of the tested outcomes, with the exception
of small for gestational age (SGA) babies, are different in the
overall populations of patients versus controls, regardless of the
chosen scale (Parazzini versus INeS charts28,29).
For the hard outcome of intrauterine
death, seven deaths were recorded overall,
of which three occurred in the control group
and four occurred in patients (P=0.44).
Three of the four intrauterine deaths in
CKD occurred in patients affected by SLE,
and one occurred in a patient with a single
kidney and normal renal function.
None of the live-born singletons born
after the 28th week died within the first
3 months after delivery. One male child, born
at 25 weeks, died of respiratory distress after
4 days (weight 500 g, Apgar scores of 3–5 at
birth); his mother was affected by SLE, with
baseline kidney function impairment (se-
rum creatinine of 2.2 mg/dl at the start of
pregnancy).
Pregnancy-Related Outcomes: CKD
Stage
Table 4 summarizes the main outcomes re-
corded across CKD stages.
The progressive worsening of outcomes
observed from CKD stage 1 to CKD stages
4–5 is significant for most of the maternal-
fetal outcomes, with the exception of the
incidence of SGA babies (significant only
for babies below the 10th centile: P=0.02).
This outcome is partially modified by the
medical policy, because intrauterine
growth restriction is one of the indica-
tions for preterm delivery and for cesar-
ean section (reaching 70% in CKD stage 2)
(Table 4).
As for maternal renal outcomes, across
the functional stages there is a trend
toward a higher risk of onset of hyper-
tension (considering only the normo-
tensive cases at baseline: 7.9% in stage 1
to 50% in stages 4–5), development or
doubling of proteinuria (20.5% in stage
1 to 86.5% in stage 3 and 70% in stages
4–5) and shift of at least one functional
stage or start of dialysis. One patient
alone (in Cagliari), already in stage 5 at
referral, started dialysis in pregnancy,
whereas three patients shifted by two
stages (two in Torino and one in Cagliari,
all in stage 2 at the start of pregnancy). The differences reach
statistical significance for hypertension and proteinuria;
however, in spite of an increasing trend, they are not statis-
tically significant in the case of stage shift and start of
dialysis, whose risk is considerably lower compared with
the other renal outcomes (7.6% in stage 1% to 20% in stages
4–5) (Table 4).
Figure 1. Flow chart of the cases reported in the two study settings.
Figure 2. Flow chart of the controls. PE, preeclampsia; PIH, pregnancy induced
hypertension.
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Pregnancy-Related Outcomes: Logistic Regression
Analyses within CKD Stage 1
In an effort to identify which factors besides kidney function
and CKD stage modulate the outcomes of patients with CKD,
we focused on the first CKD stage because of the normal renal
function.We felt that thiswould allowus tomore easily identify
the effect that other factors such as proteinuria, hypertension,
and systemic disease may exert. Table 5 reports the results of
the logistic regression analysis in patients with stage 1 CKD.
In the overall cohort of patientswith stage 1CKD, the effects
of parity, maternal age, and setting of care (with the exception
of cesarean section) are no longer significant, whereas baseline
hypertension, baseline proteinuria ($1 g/d), and the presence
of systemic disease are confirmed as significant predictors of
adverse outcomes in this cohort with normal kidney function.
Oncemore, SGAescapes fromthis rule, presumablybecause
the onset of intrauterine growth restriction is an indication for
delivery, ideally before the baby becomes “small for gestational
age.” After adjustment for proteinuria and hypertension, the
presence of a systemic disease is an independent risk for pre-
term delivery, new onset or doubling of proteinuria, and ce-
sarean section. There is also a trend toward an association of
systemic disease with increased risk for early preterm delivery,
need for the neonatal intensive care unit (NICU), and stage
shift of CKD.
Interestingly, in spite of the baseline differences in obstetric
policies, the risks of the combined outcomes are not significantly
different in the two settings, suggesting common indications to
delivery, within a different policy toward its modality (Table 5).
Comparison between Controls and Patients with Stage
1 CKD
Figures 3 and 4 report a stepwise comparison between controls
and patients with stage 1 CKD.
The increase in risk for adversepregnancy-relatedoutcomes
persists in patients with stage 1 CKD even when the patients
with themain risk factors concomitant with CKD are excluded
(hypertension, baseline proteinuria, and systemic diseases)
and when only patients who are referred early are considered
(excluding patients in whom a clinical problem may have led
to a post hoc diagnosis of CKD).
The increase is significant for the general combined outcome
(odds ratio [OR], 1.88; 95% confidence interval, 1.27 to 2.80),
suggesting the presence of a baseline risk linked to thepresence of
stage 1 CKD (Figure 3).
DISCUSSION
This study aimed to identify the characteristics associated with
risk for adverse pregnancy-related outcomes in women with
Table 2. Main baseline clinical data in the Turin and Cagliari patient cohorts
Characteristic Turin Cagliari All Patients P Value for Turin versus Cagliari
Pregnancies (n) 336 168 504
Baseline hypertension (%) 19.6 (66) 42.9 (72) 27.4 (138) ,0.001
Baseline proteinuria (g/d) 0.13 (0.01–14.6) 0.14 (0.01–5.38) 0.13 (0.01–14.6) 0.11
Proteinuria (class) 0.84
,0.3 71.1 (239) 73.1 (117) 71.8 (356)
$0.3 to ,0.5 8.0 (27) 7.5 (12) 7.9 (39)
0.5–1 8.9 (30) 6.9 (11) 8.3 (41)
1–3 8.3 (28) 10.0 (16) 8.9 (44)
$3 3.6 (12) 2.5 (4) 3.2 (16)
Median GFR (ml/min)
CKD-EPI 120 (15–186) 112 (6–145) 118 (6–186) ,0.001
Cockcroft–Gault 121 (19–396) 102 (14–302) 114 (14–396) ,0.001
Median serum creatinine (mg/dl) 0.62 (0.3–3.80) 0.70 (0.38–7.9) 0.64 (0.3–7.9) ,0.001
CKD stage ,0.001
1 78.9 (265) 62.5 (105) 73.4 (370)
2 12.8 (43) 26.2 (44) 17.3 (87)
3 6.8 (23) 8.3 (14) 7.3 (37)
4–5 1.5 (5) 3 (5) 2 (10)
Main cause of CKD (%) ,0.001
Glomerular 15.5 17.9 16.3
Interstitial 52.7 9 38.1
ADPKD 4.5 6.5 5.2
Systemic disease (%) ,0.001
SLE-collagen diseases 4.7 19 9.5
Diabetic nephropathy (type 1) 3.3 10.1 5.6
Kidney graft 3.6 3.6 3.6
Data are presented as % (n) or median (range) unless otherwise specified. CKD-EPI, Chronic Kidney Disease in Epidemiology Collaboration; ADPKD, autosomic
dominant polycystic kidney disease.
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CKD, with particular emphasis on stage 1 CKD. We sought to
determine whether adverse pregnancy outcomes in women
with stage 1 CKD were due to hypertension, proteinuria,
presence of systemic disease, or other factors associated with
CKD that are not clinically identified.
The TOCOS cohort collects patients whowere followed-up
on the basis of similar nephrologic policies in the two largest
units following CKD in pregnancy in Italy.
The differences between the control populations in the two
settings reflect the well known widespread differences in
epidemiology andobstetricmanagement andunderline theneed
to contextualize the data regarding pregnancy outcomes.30–32
Cesarean section is a main marker of such differences, and the
variability is enormous evenwithin the same country. In a recent
study in 593 US hospitals, rates varied almost 10-fold across
hospitals.32 Hence, the variations found in our study (1.5-fold
to 2-fold) are within the variability expected in multicenter
studies.30–33
Analysis of the TOCOS cohort led to three main results that
could be used as a guide for prenatal counseling and for tailoring
clinical surveillance in pregnancy (Figures 3 and 4, Tables 3–5).
The first result is confirmatory, on a much larger scale, of pre-
viously reported data. Renal function matters, and its effect is
likely to be continuous. Considering only the patientswith a live-
born baby, our data confirm a stepwise increase in pregnancy-
related risks from stage 1 to stages 4–5 (Table 3). Interestingly,
there is a significant increase in risk from stage 1 to stage 2
CKD, which represents a sort of “gray” area with regard to
kidney function.12–15
The increase in risk is observed both for maternal-fetal
outcomes, particularly prematurity, and for renal outcomes,
including the development of hypertension, proteinuria, and shift
toward a higher functional CKD stage or to dialysis. Of note,
however,eveninthehigherstages,astageshiftwasobservedinonly
about 20%ofpatients.With the limit of the small numberof cases,
this may suggest that worsening of kidney function is not an
absolute rule and thepresence of advancedCKDshouldnotbe the
only reason for counseling pregnancy termination (Table 4).
The second point specifically regards the population with
stage 1 CKD.With 370 singleton deliveries, this is probably the
Table 3. Main maternal-fetal outcomes in patients and controls
Outcome
Controls Patients P Value for
Patients versus
ControlsTurin Cagliari All P Value Turin Cagliari All P Value
Pregnancies (n) 559 277 836 336 168 504
Cesarean sections 23.1 35.4 27.2 ,0.001 42.9 78.6 54.8 ,0.001 ,0.001
Gestational week 39.261.7 38.761.8 39.061.7 ,0.001 37.362.8 36.163.1 36.962.9 ,0.001 ,0.001
Preterm (,37 wk) 4.7 9.0 6.1 0.02 27.1 46.1 33.4 ,0.001 ,0.001
Early preterm
(,34 wk)
0.7 1.4 1.0 0.45 10.4 16.8 12.5 0.06 ,0.001
Weight at birth (g) 3289.36481 3145.46465 3241.66480 ,0.001 2869.26705 2669.46758 2802.66728 0.004 ,0.001
SGA score
Parazzini
,10% 9.5 12.0 10.3 0.34 15.8 13.5 15.1 0.58 0.01
,5% 4.0 5.4 4.5 0.43 6.6 3.7 5.6 0.27 0.41
INeS
,10% 7.8 10.8 8.8 0.18 13.1 12.0 12.7 0.83 0.03
,5% 3.1 3.6 3.2 0.84 5.1 1.2 3.8 0.06 0.72
Need for NICU 1.3 2.9 1.8 0.18 16.1 18.7 16.9 0.55 ,0.001
General combined
outcome
13.6 20.3 15.9 0.02 38.7 54.5 43.9 0.001 ,0.001
Severe combined
outcome
10.6 14.5 11.9 0.13 27.7 32.9 29.4 0.27 ,0.001
New-onset
hypertension
4.3 7.9 5.5 0.05 12.2 11.5 12.0 0.99
New-onset or
doubling of
proteinuria
28.3 31.5 29.4 0.51
CKD stage shift 9.8 8.3 9.3 0.71
Data are presented as the mean6SD or percentage unless otherwise specified. ISTAT data (2010) show the following rates for cesarean sections: 37.5% in Italy,
29.9% in Piedmont, and 37.1% in Sardinia.26 The rate for preterm delivery in Italy was 6.6%. There was one case with nondetermined gestational age. SGA was not
assessed in the child with uncertain gestational age. Parazzini scores were not assessable in children born before the 28th gestational week. For new-onset
hypertension, only normotensive cases at baseline are considered. Doubling of serum creatinine occurred in three patients in the Turin cohort (diabetic
nephropathy; pancreas-kidney graft; polycystic nephropathy) and in two patients in the Cagliari cohort (one patient with GN as well as one patient who started
peritoneal dialysis in pregnancy) (P=NS). Diagnosis of preeclampsia (only controls are considered) was as follows: 1.2% in Torino-1, 1.0% in Torino-2, 2.9% in
Cagliari, and 1.7% in all controls (P=NS).
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largest currently available cohort. By definition, patients with
stage 1 CKD have normal kidney function; therefore, the
significant differences compared with the low-risk control
population demonstrate that kidney function impairment is not
the only element to be taken into consideration for risk
assessment in CKD pregnancy (Figures 3 and 4, Tables 3 and 5).
In an effort to understand whether there was a baseline risk
linked to CKD per se, we first analyzed the effect of the classic
risk factors (proteinuria, hypertension, and systemic diseases)
in a logistic analysis including only patients with stage 1 CKD.
Because the different outcomes are interrelated, we also ana-
lyzed two combined outcomes: a general outcome, including
preterm delivery, need for NICU, and SGA; and a severe out-
come, combining early preterm delivery with need for NICU
and SGA (Table 5).
Second, we performed a comparison with the low-risk
controls, progressively excluding the patients with systemic
diseases, hypertension, or proteinuria, or who were referred
late (Figures 3 and 4).
As expected, the presence of the “classic” risk factors in-
creases the odds of negative outcomes, single or combined.
However, a significant risk of general adverse outcomes per-
sists (in spite of the lower number of patients) after excluding
all of the participants with other unfavorable prognostic
markers and considering only the patients referred before
the 20th gestational week in order to avoid biases due to the
post hoc identification of CKD in patients studied for clinical
problems (Figures 3 and 4).
These data support the hypothesis that any persistent renal
damage, evenwhen associatedwith preserved kidney function,
Table 4. Comparisons across CKD stages
Characteristic
CKD Stage P Value
across Stages1 (n=370) 2 (n=87) 3 (n=37) 4–5 (n=10)
Baseline data
Maternal age (yr) 31.365.5 33.864.5 33.564.1 32.365.2 ,0.001
Parity (% nulliparous) 54.6 57.5 64.9 70.0 0.50
Referral week 15.0 (4–39) 11.0 (4–38) 8.0 (5–33) 8.0 (4–28) ,0.001
Systemic disease (%) 11.6 (43/370) 35.6 (31/87) 43.2 (16/37) 40.0 (4/10) ,0.001
Hypertension (%) 21.6 (80/370) 41.4 (36/87) 54.1 (20/37) 20.0% (2/10) ,0.001
Proteinuria (g/d)
Baseline 0.12 (0–14.6) 0.15 (0–6.8) 0.50 (0–2.8) 0.63 (0.10–3.44) ,0.001
,0.3 78.4 (286/370) 65.1 (56/86) 33.3 (12/36) 22.2 (2/9)
$0.3 to ,0.5 7.9 (29/370) 5.8 (5/86) 11.1 (4/36) 11.1 (1/9)
$0.5 to ,1.0 5.2 (19/370) 8.1 (7/86) 33.3 (12/36) 33.3 (3/9)
$1.0 to ,3.0 6.0 (22/370) 14.0 (12/86) 22.2 (8/36) 22.2 (2/9)
$3.0 2.5 (9/370) 7.0 (6/86) — 11.1 (1/9)
Maternal-fetal outcomes
Cesarean sections 48.4 70.1 78.4 70.0 ,0.001
Gestational week 37.662.6 35.763.2 34.462.4 32.664.2 ,0.001
Preterm delivery (,37 wk) 23.5 50.6 78.4 88.9 ,0.001
Early preterm (,34 wk) 7.3 20.7 37.8 44.4 ,0.001
Birth weight (g) 2966.56659 24846707 2226.36582 16396870 ,0.001
SGA score (Parazzini)
,10% 13.3 17.9 18.9 50.0 0.02
,5% 5.1 6.0 5.4 25.0 0.12
Need for NICU 10.3 27.6 44.4 70.0 ,0.001
General combined outcome 34.1 63.2 83.8 90.0 ,0.001
Severe combined outcome 21.4 44.8 59.5 80.0 ,0.001
New-onset hypertension (%) 7.9 (23/290) 17.6 (9/51) 47.1 (8/17) 50.0 (4/8) ,0.001
New-onset or doubling of proteinuria 20.5 (76/370) 37.9 (33/87) 86.5 (32/37) 70.0 (7/10) ,0.001
CKD stage shift or RRT start 7.6 (28/370) 12.6 (1/87) 16.2 (6/37) 20.0 (2/10) 0.12
Data are presented as themean6SD, percentage (proportion), ormedian (range), unless otherwise indicated. CKD stage shift indicates an increase of at least 1CKD
stage. New-onset proteinuria is defined as proteinuria increasing from a baseline level,0.3 to$0.3 g/d (calculated in patients with proteinuria,0.3 g/d). P values
through CKD stages (P1, stage 1 versus stage 2; P2, stage 2 versus stage 3; P3, stage 3 versus stages 4–5) are illustrated: Maternal age: P1,0.001; P2=1.0; P3=1.0.
Parity: P1=0.71; P2=0.57; P3=1.0. Week of referral: P1,0.001; P2=0.17; P3=0.72. Systemic disease: P1,0.001; P2=0.55; P3=1.0. Hypertension: P1,0.001;
P2=0.27; P3=0.07. Baseline proteinuria: P1=0.01; P2,0.001; P3=0.36. Cesarean section: P1,0.001; P2=0.46; P3=0.67. Gestational age: P1,0.001; P2=0.08;
P3=0.40. Preterm delivery (,37 weeks): P1,0.001; P2=0.007; P3=0.66. Early preterm (,34 weeks): P1,0.001; P2=0.007; P3=0.72. Weight at birth: P1,0.001;
P2=0.29; P3=0.08. SGA 10% (Parazzini): P1=0.36; P2=1.0; P3=0.08. SGA 5% (Parazzini): P1=0.99; P2=1.0; P3=0.05. Need for NICU: P1,0.001; P2=0.05; P3=0.30.
New-onset hypertension: P1=0.03; P2=0.02; P3=1.0. New-onset or doubling of proteinuria: P1,0.001; P2,0.001; P3=0.34.
P values stage 1 versus controls are illustrated: Maternal age: P,0.001. Parity: P=0.28. Cesarean sections, gestational age, preterm delivery (,37 weeks), early
preterm delivery (,34 weeks), birth weight, and need for NICU: P,0.001; SGA 10% (Parazzini): 0.16; SGA 5% (Parazzini): 0.70; new-onset hypertension P=0.19.
P values for combined outcomes through stages are illustrated: General combined outcome: P1,0.001; P2=0.039; P3=1.0. Severe combined outcome: P1,0.001;
P2=0.195; P3=0.289.
2016 Journal of the American Society of Nephrology J Am Soc Nephrol 26: 2011–2022, 2015
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in the absence of hypertension, significant
proteinuria or systemic disease, increases
the risk for adverse pregnancy outcomes.
The presence of such a baseline risk should
lead to the search for other markers and
disease modulators.
Finally, the third result concerns the risk
of stillbirth. We observed four cases in the
CKD population and three among the
controls. Although the prevalence is slightly
higher in patients with CKD, the difference
is not statistically significant. Of note, three
of four patients with CKD were affected by
SLE. This observation should not lead us to
underestimate the risk inpatientswithCKD,
but may scale it down, at least within the
“standard” kidney diseases.16–19
Our study has weaknesses and strengths,
in part shared by other clinical studies on
CKD and pregnancy. This study is based on
the data collected by two centers alone.
However, according to the Italian Study
Group on Kidney and Pregnancy, these are
the only ones with prospective data collec-
tion and with .100 pregnancies followed-
up since 2000.
Figure 3. Forest plot and random-effects meta-analysis of the general combined
outcome (preterm delivery, SGA, NICU) in different selections of CKD stage 1 versus
low-risk pregnancies. Results for Turin are presented as follows: all cases (OR, 2.66; 95%
CI, 1.85 to 3.83), no systemic disease (OR, 2.40; 95% CI, 1.65 to 3.50), no systemic
disease andproteinuria,1g/d (OR, 2.12; 95%
CI, 1.43 to 3.13), no systemic disease and
proteinuria ,1 g/d and normotension (OR,
1.84; 95% CI, 1.21 to 2.78), and no systemic
disease and proteinuria ,1 g/d and normo-
tension and referral within 20 gestational weeks
(OR, 2.01; 95% CI, 1.25 to 3.23). Results for
Cagliari are presented as follows: all cases (OR,
3.12; 95% CI, 1.13 to 5.01), no systemic disease
(OR, 2.71; 95% CI, 1.59 to 4.61), no systemic
disease and proteinuria,1 g/d (OR, 2.63; 95%
CI, 1.53 to 4.53), no systemic disease and pro-
teinuria ,1 g/d and normotension (OR, 1.89;
95% CI, 0.94 to 3.80), and no systemic disease
and proteinuria,1 g/d and normotension and
referral within 20 gestational weeks (OR, 2.11;
95%CI, 0.99 to 4.53). Results for both Turin and
Cagliari are presented as follows: all cases (OR,
2.67; 95% CI, 2.00 to 3.55), no systemic disease
(OR, 2.33; 95% CI, 1.72 to 3.14), no systemic
disease and proteinuria,1 g/d (OR, 2.13; 95%
CI, 1.56 to 2.91), no systemic disease and pro-
teinuria ,1 g/d and normotension (OR, 1.68;
95% CI, 1.19 to 2.38), and no systemic disease
and proteinuria,1 g/d and normotension and
referral within 20 gestational weeks (OR, 1.88;
95% CI, 1.27 to 2.79). 95% CI, 95% confidence
interval.
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A second limitation is the assessment of kidney function.
Thereare currentlynovalidated formulas inpregnancy, and the
frequent lack of preconception data prevents precise staging of
baseline CKD. However, this limitation is attributable to the
frequently late referral of patients with CKD, which is likely a
worldwideproblem.However, inaclinical context, theadvantage
of our data is that they take into consideration commonly
assessed, low-cost parameters that are readily available world-
wide.
One of the strengths of our study is the very low incidence of
patients lost to follow-up, thus guaranteeing against attrition
biases after referral. Another important point is the availability
of a large low-risk control population, allowing contextualiza-
tion of the data.
Further studies on different, large cohorts are needed both to
confirmthepresence of this baseline risk linked to stage1CKD in
the absenceofotherclassic risk factors, and tounravel itsmystery.
A prediction model should probably be the next step in this
field, analogous with what was recently developed for pre-
eclampsia, as a valuable support for counseling and for identi-
fyingpatients athigher riskbeforepregnancyorat referral during
pregnancy.34,35
Our study, which to our knowledge is likely the largest
cohort to date of prospectively collected patients with CKD,
aimed to assess the main determinants of risk in pregnancy.
Renal function matters, and a stepwise increase in the risk of
adverse maternal-fetal outcomes is observed from stage 1 to
stages 4–5. However, the risk is not merely linked to kidney
function reduction because patients with stage 1 CKD and
controls differ significantly. Furthermore, the differences are
not fully explained by the classic risk factors (proteinuria, hy-
pertension, and kidney disease), thus suggesting the presence
of a baseline risk linked to CKD per se. This observation is of
practical value because it recommends that clinicians must
take special care when treating all CKD patients in pregnancy,
even in the absence of known risk factors, and that researchers
should collect more data and test novel markers to shed light
on this fascinating mystery.
Figure 4. Forest plot and random-effects meta-analysis of the
“severe” combined outcome (early preterm delivery, SGA, NICU)
in different selections of CKD stage 1 versus low-risk pregnancies.
Results for Turin are presented as follows: all cases (OR, 2.06;
95% CI, 1.37 to 3.12), no systemic disease (OR, 1.79; 95% CI,
1.64 to 2.76), no systemic disease and proteinuria ,1 g/d (OR,
1.65; 95% CI, 1.05 to 2.59), no systemic disease and proteinuria
,1 g/d and normotension (OR, 1.47; 95% CI, 0.91 to 2.36), and
no systemic disease and proteinuria ,1 g/d and normotension
and referral within 20 gestational weeks (OR, 1.53; 95% CI, 0.87 to
2.66). Results for Cagliari are presented as follows: all cases (OR,
1.89; 95% CI, 2.00 to 3.24), no systemic disease (OR, 2.10; 95% CI,
1.16 to 3.70), no systemicdisease andproteinuria,1g/d (OR, 1.93;
95%CI, 1.06 to 3.50), no systemic disease andproteinuria,1g/d and
normotension (OR, 1.28; 95% CI, 0.57 to 2.88), and no systemic dis-
ease and proteinuria ,1 g/d and normotension and referral within
20gestational weeks (OR, 1.17; (95%CI, 0.47 to 2.87). Results for both
Turin andCagliari arepresentedas follows: all cases (OR, 1.93; 95%CI,
1.39 to 2.66), no systemic disease (OR, 1.77; 95%CI, 1.26 to 2.50), no
systemic disease and proteinuria ,1 g/d (OR, 1.66; 95% CI, 1.16 to
2.36), no systemic disease and proteinuria,1 g/d and normotension
(OR, 1.31; 95% CI, 0.88–1.96), and no systemic disease and pro-
teinuria ,1 g/d and normotension and referral within 20 gestational
weeks (OR, 1.33; 95% CI, 0.84 to 2.13).
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CONCISE METHODS
Study Settings and Referral Criteria
This study was conducted in the Maternal-Fetal Medicine Unit of the
Sant’Anna University Hospital (150 beds for obstetric patients) in
Turin, Italy,36 and in theNephrologyDepartment of the BrotzuHospital
(30 beds for nephrology and transplantation, 25 beds in obstetrics) in
Cagliari, Italy. These two settings have the broadest experience with
CKD in pregnancy in Italy. In Turin, the outpatient unit dedicated to
kidney diseases in pregnancy was established in 2000.36 In Cagliari, a
joint nephrology-obstetrics outpatient service has been active since
1989. Both units collected data prospectively. The databases were up-
dated andmerged onDecember 31, 2013, and data concerning all of the
patients referred since January 1, 2000, were selected. Complete meth-
ods are available in the Supplemental Material.
Patient and Control Populations
This study included patients with CKD with singleton pregnancies
and of gestational age .23 completed weeks. Reasons for exclusion
were as follows: ongoing pregnancy,multiple pregnancies, or preeclamp-
sia without evidence of underlying CKD. Only 13 patients were lost to
follow-up, all of whom were in Turin.
Overall, 508 pregnancies of 731 referred pregnancies (including
4 intrauterine deaths and 504 singleton deliveries) were taken into
consideration for the present analysis (Figure 1).
The controls include low-risk cases, defined as pregnancies occurring
in the absence of hypertension, obesity, diabetes, CKD, cardiovascular
diseases, or any other severe disease or condition potentially affecting
pregnancy; well controlled hypothyroidism was not considered as
relevant.36–39
Turin-1 and Turin-2 consist of low-risk singleton pregnancies
referred in 1999–2007 and in 2011–2013, respectively. The Cagliari
control cohort was selected from among the low-risk patients followed-
up by the obstetrics unit between 2009 and 2013 (random selection
of 3 samplemonths per year). Of 879 low-risk singleton pregnancies,
excluding miscarriages and lost to follow-up, 839 cases were selected
for comparison, including 3 intrauterine deaths and 836 deliveries
(Figure 2).
Definitions and Main Clinical Indications
CKD was classified according to Kidney Disease Outcomes Quality
Initiative guidelines.35 eGFR was calculated on preconception data,
when available within 3 months before conception (38% of the cases
in Torino and 57% in Cagliari) or on data at first check-up in preg-
nancy, employing the Cockcroft–Gault, Modification of Diet in Renal
Disease, and Chronic Kidney Disease Epidemiology Collaboration
formulas; the latter was chosen on account of its wider use.36,40–42
After referral, creatinine clearance and proteinuria were assessed on
24-hour urine collection.
The diagnoses of CKD and of preeclampsia were classified as
described elsewhere36; systemic diseases included diabetic nephropathy,
SLE, collagen diseases or vasculitides, and kidney transplantation.
A newborn was defined as SGA when birth weight was below the
10th percentile according to Italian birth weight references (Parazzini
scale and INeS charts).28,29 The Parazzini scale was chosen for
multivariate analysis because its use as a referral scale covers most
of our study period.
Preterm delivery was defined as before 37 completed gestational
weeks; early preterm delivery was defined as before 34 gestational
weeks.35
Prenatal and intrapartumcareof low-riskpregnancies followed the
current guidelines.43,44 The frequency of nephrologic and obstetric
visits was tailored to patients with CKD, ranging from one visit every
4–6 weeks in nonhypertensive, nonproteinuric, nonsystemic patients
with stage 1 CKD to one to two times weekly in patients with severe
proteinuria or hypertension or stages 4–5 CKD, alone or combined.
Indications for early delivery included severe worsening of
maternal and/or fetal conditions up to the 32nd week of gestational
age or less severe worsening after 32 weeks. The indications for NICU
were as follows: birth weight,1800 g, gestational age,34 weeks,
need for intubation, or other severe or potentially severe disease or
condition.
Statistical Analyses
The following data were gathered and/or calculated for patients and
controls: center, date of referral and delivery, age, parity, race, educational
level, BMI, gestational age at delivery, type of delivery, clinical compli-
cations, fetalweight, centile,Apgar index, sexof thebaby, admission to the
NICU, andoutcome. For patientswithCKD,data collection also included
serum creatinine, GFR, eGFR, CKD stage, kidney disease, and previous
follow-up.
Because no maternal or neonatal deaths and only seven intrauterine
deathswere observedoverall, we limited our analysis to pretermdelivery
(,37 and ,34 weeks), SGA babies, NICU admission, and cesarean
section.
Because the different outcomes are interrelated, we also analyzed
twocombinedoutcomes: ageneral outcome, includingpretermdelivery,
NICUandSGA;anda severeoutcome, combiningearly pretermdelivery
with NICU and SGA.
A descriptive analysis was performed as appropriate. Multivariate
logistic regression analysis was used to check for simultaneous effects
of covariates. Adjusted ORs and 95% confidence intervals were derived
from the estimated regression coefficients.
The logistic regression analyses in CKD stage 1 included the
following: systemic diseases, baseline hypertension, early versus late
referral (dichotomized at 20weeks), andbaselineproteinuria$1 g/d (this
latter cut-pointwas chosen because it is less likely to identify a pregnancy-
related disorder when assessed at baseline).45
The ORs derived from the analysis of the combined outcomes in
different subsets of patients with stage 1 CKD were plotted as a forest
plot, according to the analysisperformed separately for the twosettings
(Turin and Cagliari) and then combined according to a random-effects
model.
TheHosmer–Lemeshow test was utilized as ameasure of goodness
of fit. Models for which expected and observed event rates in sub-
groups are similar are considered “well calibrated,” and a lack of
statistical significance confirms the good fit of the model.
Statistical analyses were performed with SPSS software (version
18.0 for Windows; (SPSS Inc., Chicago IL). Significance was set
at ,0.05.
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